Analysis of Enochian Biosciences Inc’s Performance
Enochian Biosciences is focused on developing advanced allogeneic cell and gene therapies for long-term or life-long cancer remission and potentially to treat or cure serious infectious diseases. Over the past several years, the company has evolved with a significant expansion into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors. The company has progressed to the forefront of oncology development activity with the pancreatic cancer platform. The company's general approach with gene and/or cell therapy is to enhance the immune system to allow a person to better fight diseases. The company uses off-the-shelf allogeneic cells, combined with genetic modifications designed to enhance immune signaling, which could potentially generate therapeutic candidates that have unique attributes to increase the likelihood of success.
The company’s product development strategy is anchored in the use of “non-self” or allogeneic cells that enhance the immune response that they seek to elicit. Additionally, the company responds quickly to new data and perceived development opportunities and risks assessments. Based on the maturation of their pipelines, the company makes business decisions to prioritize the programs that could potentially move more rapidly through development and commercial processes.
Enochian Biosciences has an innovative gene therapy approach to enhance the selection and engraftment (uptake) of cells carrying therapeutic attributes. Enhanced uptake or engraftment could play a critical role in some cases to increase the likelihood of therapeutic benefit. The company has sublicensed under a profit-sharing agreement its technology to potentially increase engraftment for potential use in CAR-T therapy as a potential cure for HIV.
The company has laid out its plan to penetrate the effective oncology market. While it shows exceptional progress in the oncology platform, there is an excellent opportunity for the company to extend research and development in infectious diseases. In all, Enochian Biosciences has made substantial progress over the past several years and is well-positioned to enhance its market position and potential profitability.
Analysis of Enochian Biosciences Inc’s Future Outlook
Enochian Biosciences believes that the combination of off-the-shelf allogeneic cells, combined with genetic modifications designed to enhance immune signaling, could potentially generate therapeutic candidates that have unique attributes that will increase the likelihood of success. Enochian Biosciences is committed to developing advanced allogeneic cell and gene therapies through innovative gene therapy approaches.
The global gene therapy market is anticipated to grow at a healthy CAGR of around 20% over the projected period to 2025, owing to the various factors such as the need for advanced therapy for cancer and other severe chronic diseases coupled with increased funding for cell and gene therapies. The current pandemic and other newly emerging virus outbreaks have increased the need for new treatment methods that are expected to increase demand for gene therapies.
The company is making efforts to enter the oncology segment of the market, with the pancreatic cancer platform taking the lead. In the field of oncology, the annual number of new cancer cases and deaths is expected to grow significantly over the next few decades as a result of population growth and aging, as well as changes in the prevalence and distribution of the main risk factors for cancer. Chemo- and radiation therapy have been the standard of care for many forms of cancer. However, they show toxic side effects to healthy cells, which limits its ability to reach its full potential. The approach of Enochian Biosciences with gene and/or cell therapy is to enhance the immune system to allow a person to better fight diseases, more effective and potentially have fewer side effects, which is expected to increase the demand for their product.
In the near future, Enochian Biosciences is expected to be among the top competitors in a highly competitive gene therapy market. Based on data from the previous years, the company has highly competent management that has made strategic decisions that have shown progress in the company's performance. Overall, with the growing demand for gene therapies, Enochian Biosciences' highly innovative immune system enhancement approaches to overcome infectious diseases, and its promising progress in the cancer segment, the company is expected to grow at a steady rate to provide high returns to investors.